Tyr1197

Site Information
PTAENAEyLRVAPPS SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448060
Associated spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 6 , 8 , 10 , 12 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 32 ) , phospho-antibody ( 4 , 5 , 7 , 9 , 11 , 13 , 30 , 31 , 33 ) , western blotting ( 4 , 5 , 7 , 9 , 13 , 30 )
Disease tissue studied:	bladder cancer ( 13 ) , breast cancer ( 9 ) , colorectal cancer ( 11 ) , colorectal carcinoma ( 11 ) , liver cancer ( 7 ) , hepatocellular carcinoma ( 7 ) , lung cancer ( 16 , 17 ) , non-small cell lung cancer ( 16 , 17 )
Relevant cell line - cell type - tissue:	'stem, mesenchymal' ( 18 ) , 3T3 (fibroblast) ( 32 ) , 4T1 (breast cell) ( 9 ) , B82 (fibroblast) ( 33 ) , bladder ( 13 ) , C2C12-D (muscle cell) ( 27 , 28 ) , colon ( 11 ) , Hepa 1-6 (epithelial) ( 14 ) , hepatocyte-liver ( 7 ) , HTR8/SVneo (trophoblast) ( 4 ) , Huh7 (hepatic) ( 7 ) , keratinocyte-skin ( 31 ) , liver ( 6 , 8 , 23 , 24 , 25 , 26 , 29 ) , liver [Akt2 (mouse), homozygous knockout] ( 19 , 20 , 21 , 22 ) , liver [leptin (mouse), homozygous knockout] ( 8 ) , lung ( 16 , 17 ) , MDA-MB-231 (breast cell) ( 9 ) , MEF (fibroblast) [HRas (mouse), HRas V12] ( 12 ) , MEF (fibroblast) [PTP1B (mouse), homozygous knockout] ( 15 ) , MEF (fibroblast) ( 15 ) , MTLn3 (breast cell) ( 9 ) , NR6WT (fibroblast) ( 5 )

Upstream Regulation
Regulatory protein:	PTP1B (mouse) ( 15 ) , SNIP (human) ( 9 )
Putative in vivo kinases:	EGFR (mouse) ( 33 )
Phosphatases, in vitro:	PTP1B (mouse) ( 15 )
Treatments:	AG1478 ( 4 ) , cetuximab ( 13 ) , EGF ( 4 , 5 , 7 , 9 , 15 , 30 , 33 ) , light ( 13 ) , phenobarbital ( 7 ) , phorbol_ester ( 33 ) , SB202190 ( 30 ) , UV ( 31 )

Downstream Regulation
Effects of modification on biological processes:	apoptosis, inhibited ( 31 ) , carcinogenesis, induced ( 4 ) , signaling pathway regulation ( 7 ) , transcription, inhibited ( 4 )

References
1	Sluimer LM, et al. (2023) SKOR1 mediates FER kinase-dependent invasive growth of breast cancer cells. J Cell Sci 136 36620935 Curated Info
2	Jin C, et al. (2022) MTDH-stabilized DDX17 promotes tumor initiation and progression through interacting with YB1 to induce EGFR transcription in Hepatocellular Carcinoma. Oncogene 42 36385375 Curated Info
3	Celen C, et al. (2022) Arid1a loss potentiates pancreatic β-cell regeneration through activation of EGF signaling. Cell Rep 41, 111581 36323264 Curated Info
4	Fang L, et al. (2021) EGF stimulates human trophoblast cell invasion by downregulating ID3-mediated KISS1 expression. Cell Commun Signal 19, 101 34620174 Curated Info
5	Shao H, Wells A (2021) Binding of alpha-ACTN4 to EGF receptor enables its rapid phosphorylation. Heliyon 7, e06011 33532643 Curated Info
6	Wilson-Grady JT, Haas W, Gygi SP (2013) Quantitative comparison of the fasted and re-fed mouse liver phosphoproteomes using lower pH reductive dimethylation. Methods 61, 277-86 23567750 Curated Info
7	Mutoh S, et al. (2013) Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling. Sci Signal 6, ra31 23652203 Curated Info
8	Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83 23140645 Curated Info
9	Damiano L, et al. (2012) p140Cap suppresses the invasive properties of highly metastatic MTLn3-EGFR cells via impaired cortactin phosphorylation. Oncogene 31, 624-33 21725361 Curated Info
10	Zhou J (2010) CST Curation Set: 9104; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416 Curated Info
11	Rego RL, et al. (2010) Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 102, 165-72 19997103 Curated Info
12	Li Y (2009) CST Curation Set: 6299; Year: 2009; Biosample/Treatment: cell line, MEF Ras v12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
13	Bhuvaneswari R, Gan YY, Soo KC, Olivo M (2009) Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer 8, 94 19878607 Curated Info
14	Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46 18846507 Curated Info
15	Mertins P, et al. (2008) Investigation of protein-tyrosine phosphatase 1B function by quantitative proteomics. Mol Cell Proteomics 7, 1763-77 18515860 Curated Info
16	Rikova K (2008) CST Curation Set: 4439; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
17	Rikova K (2008) CST Curation Set: 4440; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
18	Yu J (2007) CST Curation Set: 3379; Year: 2007; Biosample/Treatment: cell line, Mouse Mesenchymal Stem Cells/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
19	Guo A (2007) CST Curation Set: 2987; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
20	Guo A (2007) CST Curation Set: 2988; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
21	Guo A (2007) CST Curation Set: 2989; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
22	Guo A (2007) CST Curation Set: 2990; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
23	Guo A (2007) CST Curation Set: 2983; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
24	Guo A (2007) CST Curation Set: 2984; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
25	Guo A (2007) CST Curation Set: 2985; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
26	Guo A (2007) CST Curation Set: 2986; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
27	Guo A (2007) CST Curation Set: 2564; Year: 2007; Biosample/Treatment: cell line, C2C12-D/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
28	Guo A (2007) CST Curation Set: 2565; Year: 2007; Biosample/Treatment: cell line, C2C12-D/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
29	Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93 17242355 Curated Info
30	Frey MR, Dise RS, Edelblum KL, Polk DB (2006) p38 kinase regulates epidermal growth factor receptor downregulation and cellular migration. EMBO J 25, 5683-92 17139251 Curated Info
31	El-Abaseri TB, Putta S, Hansen LA (2006) Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. Carcinogenesis 27, 225-31 16123117 Curated Info
32	Guo A (2005) CST Curation Set: 630; Year: 2005; Biosample/Treatment: cell line, 3T3/EGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
33	Li J, et al. (2003) Differential requirement of EGF receptor and its tyrosine kinase for AP-1 transactivation induced by EGF and TPA. Oncogene 22, 211-9 12527890 Curated Info